Trading analysis backed by real performance data

Vote was 241-200. The bill aligns Poland with EU crypto rules after President Nawrocki blocked earlier versions. Next step: presidential signature or another veto within 21 days.

Avant Genomics raised $3M+ for automated liquid biopsy sample prep. The round signals VC confidence in solving a key bottleneck in precision oncology. Next milestone: manufacturing scale-up and clinical validation.

CFTC data shows yen net short positions jumped 21.7% to ¥-75.1K. The carry trade remains dominant, but extreme positioning raises squeeze risk ahead of BoJ and US data.

Sterling net shorts plunged 20.8K contracts to £-43.1K, the largest weekly cover this cycle. The positioning data validates the recent GBP/USD rally. Next week's BoE meeting will determine if the unwind continues or stalls.

VolitionRx Q1 revenue ~$1M, cash $3.1M. First DETECSEPS patient expected September. $5M milestone and Nu.Q Vet/Fuji catalysts ahead. Lung cancer program also pending.

Vecima Networks published its Q3 fiscal 2026 slide deck without a press release. Investors must scan for segment revenue, margin, and guidance signals. The next catalyst is the earnings call or MD&A filing.

Private rocket company SpaceX reportedly picks Nasdaq for IPO pricing as soon as June 11. The listing could open space equities to retail investors.

Efpy's micro-dose lip balms debut on IPSY. Unilever (UL) stands to gain or lose from the category shift. Alpha Score 54 signals no clear edge.

VCs poured $10B into web3 gaming from 2021 to mid-2023. User growth stalled. The real bottleneck is visibility and distribution, not more funding rounds.

Alpha Score 47 flags divided sentiment as Devon's commodity tailwind meets execution risk. FQ2'26 results will confirm or break the Buy thesis.